[go: up one dir, main page]

WO2012022496A3 - Method for killing tumor stem cells - Google Patents

Method for killing tumor stem cells Download PDF

Info

Publication number
WO2012022496A3
WO2012022496A3 PCT/EP2011/004202 EP2011004202W WO2012022496A3 WO 2012022496 A3 WO2012022496 A3 WO 2012022496A3 EP 2011004202 W EP2011004202 W EP 2011004202W WO 2012022496 A3 WO2012022496 A3 WO 2012022496A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
tumor stem
killing tumor
killing
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/004202
Other languages
French (fr)
Other versions
WO2012022496A2 (en
Inventor
Per Sonne Holm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2012022496A2 publication Critical patent/WO2012022496A2/en
Publication of WO2012022496A3 publication Critical patent/WO2012022496A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention is related to a YB-1 dependent virus for use in a method for killing tumor stem cells of a tumor.
PCT/EP2011/004202 2010-08-19 2011-08-19 Method for killing tumor stem cells Ceased WO2012022496A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10008691.7 2010-08-19
EP10008691 2010-08-19
EP10014419.5 2010-11-09
EP10014419 2010-11-09

Publications (2)

Publication Number Publication Date
WO2012022496A2 WO2012022496A2 (en) 2012-02-23
WO2012022496A3 true WO2012022496A3 (en) 2012-06-07

Family

ID=44532745

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/004202 Ceased WO2012022496A2 (en) 2010-08-19 2011-08-19 Method for killing tumor stem cells

Country Status (1)

Country Link
WO (1) WO2012022496A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6576326B2 (en) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ Oncolytic adenovirus composition
KR20220163505A (en) 2016-02-23 2022-12-09 솔크 인스티튜트 포 바이올로지칼 스터디즈 Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
KR20210031852A (en) * 2018-03-05 2021-03-23 클리니쿰 레히츠 데어 이자르 데어 테크니쉔 우니베르지테트 뮌헨 Treatment of tumors with the combination of tumor cytolytic adenovirus and CDK4/6 inhibitor
CN112292449A (en) 2018-04-09 2021-01-29 萨克生物研究学院 Oncolytic adenovirus compositions with enhanced replication properties
US20220354911A1 (en) * 2019-09-05 2022-11-10 Klinikum Rechts Der Isar Der Technischen Universität München Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1695978A1 (en) 1990-06-11 2006-08-30 Gilead Sciences, Inc. Nucleic acid ligands
DE69426841T2 (en) 1993-02-16 2001-09-06 Onyx Pharma Inc Cytopatic viruses for the therapy and prophylaxis of neoplasia
US5838165A (en) 1996-08-21 1998-11-17 Chatter; Mukesh High performance self modifying on-the-fly alterable logic FPGA, architecture and method
DE59708838D1 (en) 1996-08-30 2003-01-09 Jens Peter Fuerste MIRROR SELECTION AND MIRROR EVOLUTION OF NUCLEIC ACIDS
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
DE10150984A1 (en) 2001-10-16 2003-04-17 Holm Per Sonne Expressing foreign nucleic acids with the adenoviral E2 late promoter, useful in the treatment of tumors, comprises selective activation by Y-box-binding protein-1 in tumor cell nuclei
EP1506021B1 (en) 2002-05-27 2019-05-01 Per Sonne Holm Use of adenoviruses and nucleic acids coding therefor
PL219321B1 (en) 2002-10-15 2015-04-30 Per Sonne Holm Adenovirus expressing genes in reverse order and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JIANG H ET AL: "Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: Role of autophagic cell death", JOURNAL OF THE NATIONAL CANCER INSTITUTE 200709 GB LNKD- DOI:10.1093/JNCI/DJM102, vol. 99, no. 18, September 2007 (2007-09-01), pages 1410 - 1414, XP002670759, ISSN: 0027-8874 *
RIBACKA CAMILLA ET AL: "Virotherapy as an approach against cancer stem cells", CURRENT GENE THERAPY, BENTHAM SCIENCE PUBLISHERS LTD, NL, vol. 8, no. 2, 1 April 2008 (2008-04-01), pages 88 - 96, XP009135177, ISSN: 1566-5232 *
ROGNONI E ET AL: "Adenovirus-based virotherapy enabled by cellular YB-1 expression in vitro and in vivo", CANCER GENE THERAPY, vol. 16, no. 10, October 2009 (2009-10-01), pages 753 - 763, XP002670760, ISSN: 0929-1903 *

Also Published As

Publication number Publication date
WO2012022496A2 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
IL277184A (en) Method of cryopreserving cells
EP2614064B8 (en) Inhibitors of human immunodeficiency virus replication
DK3590472T3 (en) Heart valve prosthesis
LT3023102T (en) IBAT INHIBITORS FOR HUMAN DISEASES
ZA201209596B (en) Napht-2-ylacetic acid derivatives to treat aids
PT2611906T (en) Systemic, allogenic stem cell therapies for treatment of diseases in animals
WO2012129341A3 (en) Disease detection in plants
WO2011119738A9 (en) Methods of treatment using stem cell mobilizers
IL225972A0 (en) Salts of kukoamine b, preparation method and use thereof
WO2012022496A3 (en) Method for killing tumor stem cells
EP2731429A4 (en) Compounds, methods of making, and methods of use
ZA201406382B (en) Levoisovalerylspiramycin i,ii,iii and preparations ,preparation methods and uses thereof
WO2012096960A3 (en) Stem cell factor inhibitor
WO2011153429A9 (en) Methods of treatment
WO2011130697A3 (en) Tissue targeting
WO2014033158A3 (en) Pcsk9 peptide vaccine
SG11201403370YA (en) Induced pluripotent stem cells prepared from human kidney-derived cells
WO2012166659A3 (en) Anti-emr1 antibodies
EP2756092A4 (en) Methods of making cells, tissues, and antibodies
AU2012901130A0 (en) A composition and method for enhancing the permeability of a tissue of a subject to an active agent
AU2012902719A0 (en) Preparations comprising adipose tissue-derived stem cells and methods of their use
HK1196139A (en) Antibodies to pcsk9 and uses thereof
AU2010903003A0 (en) Sequenced vaso-stimulii therapy
AU2010901837A0 (en) Methods of treatment
HK1180577A (en) Percutaneously deliverable heart valve and methods associated therewith

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11749347

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11749347

Country of ref document: EP

Kind code of ref document: A2